Long-Term Effectiveness and Safety of Weekly Adalimumab in Refractory Non-Infectious Uveitis
Weekly adalimumab treatment is a viable option for managing inflammation in refractory uveitis, providing enhanced efficacy to the standard dose in terms of visual and anatomical outcomes, while maintaining a comparable side effect profile.
Authors
- Hilal Eser-Öztürk (ORCID: https://orcid.org/0000-0002-0050-7894)
- Bilge Eraydın (ORCID: https://orcid.org/0000-0003-0036-056X)
- Abdülcemal Gürpınar (ORCID: https://orcid.org/0000-0002-7451-3824)
- Yüksel Süllü (ORCID: https://orcid.org/0000-0001-9818-671X)
- Mertcan Esenkaya (ORCID: https://orcid.org/0000-0002-3888-4492)
Institutions
- Ondokuz Mayıs University (TR)
- State Hospital (GB)
- Ordu University (TR)
Publication Details
- Journal
- Ocular Immunology and Inflammation
- Published
- 2025-06-13
- DOI
- https://doi.org/10.1080/09273948.2025.2516826
- Citations
- 1
- Primary Topic
- Ocular Diseases and Behçet’s Syndrome
- Type
- article
- Field-Weighted Citation Impact
- 1.71